In conclusion, our current findings demonstrate that glycosylation-induced alterations in CaV3.2 channels in sensory neurons in vivo may directly influence diabetic hyperalgesia, and that glycosylation inhibitors can be used to ameliorate painful symptoms in Type 1 diabetes. This evidence concerns the gene CACNA1H and type 1 diabetes mellitus.